MDR_REPORT_KEY|MDR_TEXT_KEY|TEXT_TYPE_CODE|PATIENT_SEQUENCE_NUMBER|DATE_REPORT|FOI_TEXT|BRAND_NAME|CATALOG_NUMBER|DATE_RECEIVED|DATE_REMOVED_FLAG|DATE_RETURNED_TO_MANUFACTURER|DEVICE_AGE_TEXT|DEVICE_AVAILABILITY|DEVICE_EVALUATED_BY_MANUFACTUR|DEVICE_EVENT_KEY|DEVICE_OPERATOR|DEVICE_REPORT_PRODUCT_CODE|DEVICE_SEQUENCE_NO|EXPIRATION_DATE_OF_DEVICE|GENERIC_NAME|IMPLANT_FLAG|LOT_NUMBER|MANUFACTURER_D_ADDRESS_1|MANUFACTURER_D_ADDRESS_2|MANUFACTURER_D_CITY|MANUFACTURER_D_COUNTRY_CODE|MANUFACTURER_D_NAME|MANUFACTURER_D_POSTAL_CODE|MANUFACTURER_D_STATE_CODE|MANUFACTURER_D_ZIP_CODE|MANUFACTURER_D_ZIP_CODE_EXT|MODEL_NUMBER|OTHER_ID_NUMBER|filter
6233845|64197775|N|1||THE EVENTS OF LYMPHOMA CAPSULAR CONTRACTURE AND EDEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST FORMATION OF FIBROUS TISSUE AROUND AN IMPLANTED DEVICE IS A NORMAL PHYSIOLOGICAL RESPONSE FIBROUS CAPSULAR CONTRACTURE REMAINS A COMMON COMPLICATION FOLLOWING BREAST IMPLANT SURGERY AND IS ONE OF THE MOST COMMON REASONS FOR REOPERATION THE CAUSE OF CAPSULAR CONTRACTURE IS UNKNOWN HOWEVER IT IS MOST LIKELY MULTIFACTORIAL AND MAY BE MORE COMMON FOLLOWING INFECTION HAEMATOMA AND SEROMA CONTRACTURE DEVELOPS TO VARYING DEGREES UNILATERALLY OR BILATERALLY AND MAY OCCUR WITHIN WEEKS TO YEARS AFTER SURGERY CONTRACTURE OF THE FIBROUS CAPSULAR TISSUE SURROUNDING THE IMPLANT MAY CAUSE A RANGE OF SYMPTOMS INCLUDING FIRMNESS DISCOMFORT PAIN DISTORTION PALPABILITY ANDOR DISPLACEMENT SEVERE CASES ARE CONSIDERED THE MOST CLINICALLY SIGNIFICANT AND MAY REQUIRE SURGICAL INTERVENTION CAPSULAR CONTRACTURE MAY RECUR SUBSEQUENT TO CORRECTIVE SURGICAL PROCEDURES DO NOT TREAT CAPSULAR CONTRACTURE BY EXTERNAL COMPRESSION OR MASSAGE WHICH MAY RESULT IN IMPLANT DAMAGE DEFLATION FOLDS ANDOR HAEMATOMA|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|UNK STYLE 110|01/09/2017|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6247187|64666746|N|1||IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP IS BEING PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT AND PATIENT DETAILS IS BEING REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX115-290|01/12/2017|||DA|N|R||0HP|FTR|1.0|09/04/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1321464|KILBRIDE INDUSTRIAL ESTATE||ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
6257136|64954239|N|1||DEVICE HISTORY RECORD DHR DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM THIS WORK ORDER WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS THE EVENTS OF LATE SEROMA AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|STYLE 150 EXPANDABLE BREAST IMPLANT|N-27-150386|01/17/2017||||N|R||0HP|FTR|1.0|03/26/2017|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2262674|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6247063|64661472|N|1||IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP IS BEING PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAVE BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME THE EVENTS OF SEROMA AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|01/12/2017||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6247063|64661472|N|1||IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP IS BEING PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAVE BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME THE EVENTS OF SEROMA AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TSLP280|01/12/2017|||DA|*|*||0HP|FTR|1.0|05/27/2015|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1845063|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6247160|64710080|N|1||B6 -WEIGHT FLUCTUATIONS THE EVENTS OF WEIGHT LOSS ANEMIA CAPSULAR CONTRACTURE AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST FORMATION OF FIBROUS TISSUE AROUND AN IMPLANTED DEVICE IS A NORMAL PHYSIOLOGICAL RESPONSE FIBROUS CAPSULAR CONTRACTURE REMAINS A COMMON COMPLICATION FOLLOWING BREAST IMPLANT SURGERY AND IS ONE OF THE MOST COMMON REASONS FOR REOPERATION THE CAUSE OF CAPSULAR CONTRACTURE IS UNKNOWN HOWEVER IT IS MOST LIKELY MULTIFACTORIAL AND MAY BE MORE COMMON FOLLOWING INFECTION HAEMATOMA AND SEROMA CONTRACTURE DEVELOPS TO VARYING DEGREES UNILATERALLY OR BILATERALLY AND MAY OCCUR WITHIN WEEKS TO YEARS AFTER SURGERY CONTRACTURE OF THE FIBROUS CAPSULAR TISSUE SURROUNDING THE IMPLANT MAY CAUSE A RANGE OF SYMPTOMS INCLUDING FIRMNESS DISCOMFORT PAIN DISTORTION PALPABILITY ANDOR DISPLACEMENT SEVERE CASES ARE CONSIDERED THE MOST CLINICALLY SIGNIFICANT AND MAY REQUIRE SURGICAL INTERVENTION CAPSULAR CONTRACTURE MAY RECUR SUBSEQUENT TO CORRECTIVE SURGICAL PROCEDURES DO NOT TREAT CAPSULAR CONTRACTURE BY EXTERNAL COMPRESSION OR MASSAGE WHICH MAY RESULT IN IMPLANT DAMAGE DEFLATION FOLDS ANDOR HAEMATOMA GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|27-120601|01/12/2017||01/26/2017|DA|R|Y||0HP|FTR|1.0|04/15/2007|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||146123|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6247152|64673720|N|1||B4 THE EVENTS OF WEIGHT LOSS ANEMIA CAPSULAR CONTRACTURE LYMPHADENOPATHY AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST FORMATION OF FIBROUS TISSUE AROUND AN IMPLANTED DEVICE IS A NORMAL PHYSIOLOGICAL RESPONSE FIBROUS CAPSULAR CONTRACTURE REMAINS A COMMON COMPLICATION FOLLOWING BREAST IMPLANT SURGERY AND IS ONE OF THE MOST COMMON REASONS FOR REOPERATION THE CAUSE OF CAPSULAR CONTRACTURE IS UNKNOWN HOWEVER IT IS MOST LIKELY MULTIFACTORIAL AND MAY BE MORE COMMON FOLLOWING INFECTION HAEMATOMA AND SEROMA CONTRACTURE DEVELOPS TO VARYING DEGREES UNILATERALLY OR BILATERALLY AND MAY OCCUR WITHIN WEEKS TO YEARS AFTER SURGERY CONTRACTURE OF THE FIBROUS CAPSULAR TISSUE SURROUNDING THE IMPLANT MAY CAUSE A RANGE OF SYMPTOMS INCLUDING FIRMNESS DISCOMFORT PAIN DISTORTION PALPABILITY ANDOR DISPLACEMENT SEVERE CASES ARE CONSIDERED THE MOST CLINICALLY SIGNIFICANT AND MAY REQUIRE SURGICAL INTERVENTION CAPSULAR CONTRACTURE MAY RECUR SUBSEQUENT TO CORRECTIVE SURGICAL PROCEDURES DO NOT TREAT CAPSULAR CONTRACTURE BY EXTERNAL COMPRESSION OR MASSAGE WHICH MAY RESULT IN IMPLANT DAMAGE DEFLATION FOLDS ANDOR HAEMATOMA|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|27-120601|01/12/2017||01/26/2017|DA|R|Y||0HP|FTR|1.0|04/15/2007|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||146123|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
1060667|868720|D|1||I DEVELOPED FIBROMYALGIA AND A RARE FORM OF CANTANIOUS T-CELL LYMPHOMA CALLED LYMPHOMATOID PAPULOSIS AFTER A MAMMOGRAM RUPTURED A 20 YR OLD  SILICONE BREAST IMPLANT THIS RARE FORM OF LYMPHOMA AFFECTS ONLY ONE PERSON IN 12-19 MILLION IN POPULATION I HAVE SPOKEN TO 5 WOMEN THAT HAVE DEVELOPED THIS RARE LYMPHOMA AFTER THEIR SILICONE IMPLANTS RUPTURED I MET THESE WOMEN ON A SUPPORT GROUP FOR THIS RARE CANCER THERE IS ONLY ABOUT 800 KNOWN CASES IN THE WORLD SO THAT MAKES THIS A TRUE POSSIBLE RISK OF SILICONE I HAVE LARGE DEEP SKIN LESIONS ALL OVER MY BODY AND LESIONS INTERNALLY AS WELL DOW CORNING 400CC ROUND BREAST IMPLANT IMPLANTED IN 1974 THE PTS IMPLANT WAS RUPTURED IN 1993 DURING A MAMMOGRAM TO CHECK ITS INTEGRITY I DEVELOPED A RARE CANTANIOUS T-CELL LYMPHOMA CALLED LYMPHOMATOID PAPULOSIS WITHIN JUST WEEKS AFTER THE IMPLANT WAS RUPTURED I FINALLY FOUND A DOCTOR TO REMOVE THE RUPTURED IMPLANT IN 1998 THE SURGEON HAD TO REMOVE THE LOOSE SILICONE GEL WITH GLOVED HANDS AND WAS UNABLE TO REMOVE ALL THE SILICONE I HAVE MAY OTHER PROBLEMS INCLUDING FIBROMYALGIA RAYNAUDIS DIGESTIVE METABOLIC SLEEP SEIZURES AND OTHER NEUROLOGICAL PROBLEMS I AM COMPLETELY DISABLED AND HAVE NOT BEEN ABLE TO WORK SINCE 1994 AND AM CONTINUING TO GET WORSE I HAVE HAD TO TAKE WEEKLY CHEMO THERAPY METHOTREXATE FOR THE PAST 10 YEARS TO CONTROL THE MANY SEVERE SKIN LESIONS THAT I GET ALL OVER MY BODY INSIDE AND OUT DIAGNOSIS OR REASON FOR USE LEFT BREAST DID NOT DEVELOP- TO GIVE A MORE NORMAL EVENT ABATED AFTER USE STOPPED NO|DOW CORNING|*|06/12/2008|V|||Y||1029822.0|0HP|FTR|1.0||SILICONE BREAST IMPLANT|Y|*|*||*|*|DOW CORNING|||||*|*|True
2338306|2365004|D|1||A REPORT OF LYMPHOMA OF THE BREAST CAPSULE IN SILICONE IMPLANT-RECONSTRUCTED PT PUBLISHED IN THE AMERICAN SURGEON SEPT 2010 VOL 76 PG 1030-31 WAS REVIEWED AND ADDL INFO HAS BEEN REQUESTED BY THE AUTHOR THE AUTHOR HAS NOT RESPONDED TO THIS DATE WITHIN THE ARTICLE THE AUTHOR NOTES A B6 WOMAN WITH A TISSUE DIAGNOSIS OF ADENOCARCINOMA OF THE LEFT BREAST UNDERWENT A LEFT MODIFIED RADICAL MASTECTOMY WITH PROPHYLACTIC RIGHT BREAST SIMPLE MASTECTOMY IN 1999 THIS WAS IMMEDIATELY FOLLOWED BY PRIMARY RECONSTRUCTION WITH SILICONE IMPLANTS THE LYMPH NODE BASIN WAS FREE OF DISEASE AND THE PT RECEIVED NO CHEMOTHERAPY OR RADIATION THERAPY SIX YEARS LATER SHE PRESENTED TO HER PRIMARY CARE WITH A LUMP IN HER RECONSTRUCTED RIGHT BREAST ON EXAMINATION SHE HAD A 3CM NON-TENDER MOBILE CYSTIC MASS IN THE RIGHT BREAST AT THE 9 OCLOCK POSITION COMPRESSION OF THE IMPLANT CAUSED ENLARGEMENT OF THE LESION SHE DID NOT REPORT NIPPLE DISCHARGE OR RETRACTION THE SKIN AND AREOLA COMPLEX WERE NORMAL AND THERE WERE NO PALPABLE LYMPH NODES HER PRIMARY CARE PHYSICIAN PERFORMED A NEEDLE ASPIRATION OF THE MASS WHICH WAS ORANGE IN COLOR WITH CYTOLOGIC FEATURES OF ADENOCARCINOMA SHE UNDERWENT BILATERAL IMPLANT REMOVAL EXCISION OF THE CYSTIC MASS AND BIOPSIES OF BOTH CAPSULES THE LEFT BREAST IMPLANT WAS INTACT AND THE CAPSULE WAS NORMAL IN APPEARANCE THE RIGHT BREAST IMPLANT WAS INTACT AS WELL HOWEVER THE ANTERIOR AND POSTERIOR WALLS OF THE CAPSULE WERE COATED WITH A NECROTIC HETEROGENEOUS MATERIAL INITIAL BIOPSIES OF THE RIGHT BREAST CAPSULE SHOWED POORLY DIFFERENTIATED ADENENOCARCINOMA IT WAS IMMUNOPOSITIVE FOR CD30 EMA AND T-CELL MARKERS CD45RO CD43 FINAL PATHOLOGY OF THE MASS AFTER REVIEW BY A SECOND PATHOLOGIST AT A UNIVERSITY HOSPITAL WAS ANAPLASTIC LARGE CELL LYMPHOMA ALK- T CELL PHENOTYPE THE POST OP RECOVER WAS UNEVENTFUL THE PT HAD A COURSE OF CHOP PROTOCOL OUR PTS LYMPHOMA WAS DISCOVERED AS A CYSTIC LESION INVOLVING THE RIGHT BREAST CAPSULE THE PRELIMINARY CYTOLOGIC FEATURE OF THE LESION WAS POORLY DIFFERENTIATED ADENENOCARCINOMA SIMILAR TO THE PRIOR DIAGNOSIS OF THE LEFT BREASTONLY AFTER IMMUNOHISTOCHEMISTRY OF THE SPECIMEN WAS SHE CORRECTLY DIAGNOSED WITH ALCL T-CELL LYMPHOMA AND TREATED WITH CHOP CHEMOTHERAPY PROTOCOL|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|11/09/2011|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
2163717|2109276|D|1||MEDWATCH REPORT RECEIVED ON B4 2011 B4 FROM HEALTHCARE PROFESSIONAL REPORTING THE FOLLOWING NON HODGKINS LYMPHOMA FELT TO BE CAUSED BY SILICONE BREAST IMPLANT PLACED IN 2003 I CALLED THE OFFICE AND SPOKE WITH MEDICAL STAFF WHO REPORTS THAT THE DEVICE WAS REMOVED ON B6 2011 AND THE DOCTOR BELIEVES THE SALINE IN THE BREAST IMPLANT WAS A PROBABLE CAUSE THAT LEAD TO HER LYMPHOMA IT IS UNKNOWN IF THE DEVICE IS AVAILABLE FOR RETURN AFTER SEVERAL ATTEMPTS TO OBTAIN FURTHER INFORMATION FROM THE OFFICE THE PATIENTS OPERATIVE REPORT PROGRESS NOTES WITH PATIENT HISTORY WERE RECEIVED VIA FAX THE DIAGNOSIS OF ANAPLASTIC LARGE T-CELL LYMPHOMA WAS MADE ON THE ASPIRATES I NOTE THIS IS ALK-STATUS ON B6 2011 SHE UNDERWENT HER FIRST CYCLE OF CHOP ACCORDING TO THE NOTES DATED B6 2011 SHE HAD COMPLETED 3 CYCLES OF CHOP TREATMENT ON B6 2011 SHE HAD A LEFT BREAST EXPLORATION AND IMPLANT REMOVAL IN ADDITION TO THIS SHE IS HAVING A LARGE MATTED AXILLARY NODE THAT WILL SAMPLED THE RIGHT BREAST IMPLANT WAS REMOVED DURING AN EARLIER PROCEDURE ACCORDING TO A CONVERSATION WITH THE OFFICE HOWEVER THE DAY OF SURGERY IS UNKNOWN PATHOLOGY REPORT HAS BEEN REQUESTED BUT NOT YET BEEN RECEIVED THE PATIENT IS SCHEDULED TO HAVE STEM CELL TRANSPLANT AND RADIATION TREATMENT PATIENT IS DOING WELL AT THIS TIME|STYLE 168 SALINE FILLED BREAST IMPLANT|168-330|06/28/2011|||DA|N|R||0HP|FWM|1.0|02/27/2007|nan||560018|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
2722372|2989693|D|1||ANAPLASTIC LARGE T-CELL LYMPHOMA ASSOCIATED WITH A SALINE-TYPE BREAST IMPLANT ABOUT 2 YEAR HISTORY OF RECURRENT EFFUSION SURROUNDING THE PROTHESIS BEFORE REMOVAL LYMPHOMA CELLS CONFINED TO THE FIBRINOUS EFFUSION WITHOUT MEASUREABLE MASS IMPLANT CAPSULE OR SOFT TISSUE INVASION OR LYMPHADENOPATHY PROGNOSIS IS FAVORABLE DATES OF USE 2 YEARS REASON FOR USE RECURRENT BREAST ABSCESS|MCGHAN||08/27/2012||||Y|||0HP|FTR|1.0||SALINE BREAST PROSTHESIS, 560 CC|||||||MCGHAN|||||||True
3030978|54657878|D|1||THROUGH MY RESEARCH REVIEW AS RN PRODUCT SUPPORT SPECIALIST THE FOLLOWING ARTICLE CAME TO MY ATTENTION SEROMA-ASSOCIATED PRIMARY ANAPLASTIC LARGE-CELL LYMPHOMA ADJACENT TO BREAST IMPLANTS AN INDOLENT T-CELL LYMPHOMA PROLIFERATIVE DISORDER BY ANJA RODEN ET AL MODERN PATHOLOGY 2008 21 455-463 WITHIN THE ARTICLE THE AUTHOR PRESENTS 4 PATIENTS WITH PRIMARY ANAPLASTIC LARGE-CELL LYMPHOMA OF THE BREAST ASSOCIATED WITH A BREAST IMPLANT AND SEROMA|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|11/20/2012|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||GOLETA|US|UNKNOWN MANUFACTURER||CA|||||True
3516781|15024064|D|1||LEGAL DOCUMENTS RECEIVED BY ALLERGAN NOTE A CASE OF LYMPHOMA THE DOCUMENTS STATE THAT ON B6 2002 THE PATIENT WAS IMPLANTED WITH MCGHAN 468 IMPLANTS ON OR ABOUT B62011 THE PATIENT WAS DIAGNOSED WITH ABNORMAL T-CELL WHICH ARE LARGE IN SIZE AND CONSISTENT WITH T-CELL LYMPHOMA PARTICULARLY ALCL A RADIOLOGY SCHEDULING FORM PREPARED FOR EMORY HEALTHCARE ON B6 2011 DESCRIBES THE DIAGNOSIS AS T-CELL LYMPHOMA AND BREAST IMPLANTS AT THIS TIME FURTHER INVESTIGATION CANNOT TAKE PLACE DUE TO THE LACK OF INFORMATION PROVIDED IF ADDITIONAL INFORMATION IS OBTAINED IT WILL BE REVIEWED AND REPORTED|STYLE 468 SALINE FILLED BREAST IMPLANT|468-495|11/22/2013|||DA|N|R||0HP|FWM|0.0||nan||NI|||GOLETA, NE||ALLERGAN||CA|||||True
3883642|4565748|D|1||ADDITIONAL INFO RECEIVED FROM A LITERATURE ARTICLE ANAPLASTIC LARGE CELL LYMPHOMA AND BREAST IMPLANTS FIVE AUSTRALIAN CASES PUBLISHED IN THE PLASTIC AND RECONSTRUCTIVE SURGERY ON B6 2012 PG 610E-617E WITHIN THE ARTICLE THE AUTHOR DESCRIBES A B6 WHO UNDERWENT BILATERAL AUGMENTATION WITH 110-360 INAMED TEXTURED ROUND DEVICES VIA INFRAMAMMARY INTO A SUB GLANDULAR POCKET IN B6 2008 THE PT PRESENTED WITH SPONTANEOUS LEFT BREAST SWELLING ALTHOUGH SHE WAS WITH ON FEVER AND MILD DISCOMFORT THE LEFT BREAST WAS DIFFUSELY SWOLLEN THE PT HAD A NORMAL MAMMO IN 2008 AND IN 2009 ULTRASOUND REVEALED A SEROMA A CT SCAN SHOWED AN INFOLDING OF THE IMPLANT BETWEEN 7 AND 9 OCLOCK WITH AN APPARENT MASS WITH SLIGHTLY INCREASED DENSITY IN B6 2009 SURGERY WAS PLANNED TO REMOVE THE PRESUMED RUPTURED IMPLANT AT THE TIME OF SURGERY A STRAW COLORED SEROMA OF 200CC WAS FOUND THE IMPLANT WAS INTACT WITHIN THE CAPSULE THERE WERE TWO AREAS OF GRANULOMATOUS TISSUE AND THICK MASS INFEROMEDIALLY THE CAPSULE AND MASS WERE SENT TO MICROBIOLOGY CULTURE AND HISTOPATHOLOGY THE LYMPHOID CELLS WERE HIGHLY ATYPICAL SHOWING ENLARGED AND IRREGULARLY CONFIGURED NUCLEI IMMUNOHISTOCHEMICAL ANALYSIS SHOWED CD30 + ALK- B-CELL MARKER NEGATIVE AND T-CELL MARKER PARTIAL AND PATCHILY-POSITIVE CD3 CD43 CD45RO AND CD5 TISSUE THE FINDINGS WERE CONSISTENT WITH LOCALIZED FORM OF SYSTEMIC ALCL LARGE T-CELL LYMPHOMA THE BREAST HEALED BUT A RECURRENT MASS APPEARED WEEKS LATER STAGING CT OF CHEST ABD PELVIS AND PET SCAN SHOWED NO EVIDENCE OF DISEASE OUTSIDE THE BREAST SHE UNDERWENT CHEMO WITH CYCLOPHOSPHAMIDE DOXORUBICIN VINCRISTINE AND PREDNISONE IN B6 2009 THE MASS FAILED TO RESPOND AND PROGRESSED TO A WOUND THE LYMPHOMA METASTASIZED TO THE THORACOLUMBAR REGION AND THE RIGHT LUNG AS SEEN IN THE B6 2009 PET SCAN SHE WAS TREATED WITH RADIATION AND A SECOND ROUND OF CHEMO USING GEMCITABINE IFOSFAMIDE AND VINORELBINE SHE RESPONDED WELL AND UNDERWENT A BONE MARROW TRANSPLANT IN 122009 TWO YEARS AFTER DIAGNOSIS SHE REMAINS IN REMISSION THIS EVENT WAS ORIGINALLY SUBMITTED VIA B4 ON B4 2011|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|27-110361|06/18/2014|||DA|N|R||0HP|FTR|1.0|09/30/2010|nan||1148082|||ARKLOW, COUNTY, WICKLOW|EI|ALLERGAN|||||||True
3642249|17838426|D|1||EVENT OF ANAPLASTIC LARGE CELL LYMPHOMA REPORTED IN JOURNAL ARTICLE PRIMARY AND SECONDARY T-CELL LYMPHOMAS OF THE BREAST GABRIELA ET AL APPL IMMUNOHISTOCHEM MOL MORPHOL VOLUME 17 NUMBER 4 JULY 2009 ALTHOUGH THE MFR OF THE DEVICE IS UNK IT IS ALLERGANS APPROACH TO COMPLIANCE TO RESOLVE ALL DOUBT IN FAVOR OF REPORTING|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|02/05/2014|||DA|N|R||0HP|FTR|1.0||nan||NI|||GOLETA|US|ALLERGAN||CA|||||True
4838209|20777628|D|1||DIAGNOSIS OF T-CELL LYMPHOMA ANAPLASTIC REFRACTORY TO CHEMOTHERAPY|UNKNOWN BREAST IMPLANT||06/05/2015|||||||0|FWM|1.0||NONE|||||||nan|||||||True
5067426|25380332|N|1||B4 DEVICE LABELING ADDRESSES ADDITIONAL COMPLICATIONS - AFTER BREAST IMPLANT SURGERY THE FOLLOWING MAY OCCUR ANDOR PERSIST WITH VARYING INTENSITY ANDOR FOR A VARYING LENGTH OF TIME PAIN HEMATOMASEROMA CHANGES IN NIPPLE AND BREAST SENSATION IMPLANT EXTRUSION NECROSIS DELAYED WOUND HEALING AND BREAST TISSUE ATROPHYCHEST WALL DEFORMITY CALCIUM DEPOSITS CAN FORM IN THE TISSUE CAPSULE SURROUNDING THE IMPLANT WITH SYMPTOMS THAT MAY INCLUDE PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS LYMPHOMAS INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL Â¿ INFORMATION FROM THE MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF 20 CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THIS DISEASE IS EXCEPTIONALLY RARE AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO IDENTIFY ALCL FROM OTHER CANCERS OF THE BREAST IT IS IMPORTANT TO NOTE THAT THESE FINDINGS ARE CONSIDERED PRELIMINARY THE MAJORITY OF THE CASES REPORTED IN PATIENTS WITH BREAST IMPLANTS PRESENT AS LATE OCCURRING SEROMAS AND HAVE AN INDOLENT CLINICAL COURSE INCLUDING SOME INVOLVING SPONTANEOUS REMISSION WITHOUT ADJUVANT THERAPY NO STUDY HAS CONCLUDED A CAUSE AND EFFECT RELATIONSHIP BETWEEN ALCL AND BREAST IMPLANTS ALL PERTINENT FINDINGS RESPECTING CASES ASSOCIATED WITH ALLERGAN DEVICES SHOULD BE REPORTED TO ALLERGAN EG TIME TO CLINICAL PRESENTATION SIGNS OR SYMPTOMS IMMUNOHISTOLOGICAL ANALYSIS TYPE OF IMPLANT TEXTURE PATIENT HISTORY WITH IMPLANTS PHYSICIANS SHOULD KEEP ABREAST OF ALCL IN THE LITERATURE AND PROVIDE APPROPRIATE THERAPY TO PATIENTS AS NEEDED|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MM120-280|09/10/2015||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4742777|16542156|D|1||JOURNAL ARTICLE ANAPLASTIC LARGE-CELL LYMPHOMA IN WOMEN WITH BREAST IMPLANTS DEJONG ET ALB6 2008 JOURNAL AMERICAN MEDICAL ASSOCIATION REPORTS ANAPLASTIC LARGE T-CELL LYMPHOMA DIAGNOSED ON THE RIGHT SIDE STAGE IV REPORT DEVICE WAS TEXTURED SILICONE MCGHAN|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|04/30/2015|||DA|N|R||0HP|FTR|1.0||nan||NI|LA AURORA DE HEREDIA||NE|CS|ALLERGAN|||||||True
5286954|40348295|N|1||MEDWATCH SENT TO FDA ON 3142016 THE PHYSICIAN DID NOT CONFIRM WHETHER THE DEVICE WAS EXPLANTED BUT DID CONFIRM THAT THE DEVICE WOULD NOT BE RETURNED THEREFORE NO ANALYSIS OR TESTING WILL BE DONE THESE EVENTS ARE BEING REPORTED BECAUSE MEDICAL INTERVENTION WAS REQUIRED ALTHOUGH DEVICE-RELATEDNESS HAS NOT BEEN ESTABLISHED THE EVENTS OF SEROMA GRANULOMATOUS REACTION AND LIPOPHAGIC NECROSIS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL -- INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION INFLAMMATORY REACTION STUDIES EVALUATING THE CAPSULES AROUND TEXTURED IMPLANTS HAVE REPORTED POSSIBLE SILICONE PARTICLES WITHIN GIANT CELLS INDICATIVE OF A LOCAL AND NONSPECIFIC FOREIGN BODY REACTION AND SILICONE GRANULOMA FORMATION IN CASE OF AN INFLAMMATORY REACTION THE SURGEON IS ADVISED TO REMOVE THE DEVICE FROM THE PATIENTS BODY AND TO SECURE ANY EVIDENCE ON THE POSSIBLE CAUSE OF THE INFLAMMATORY REACTION AND TO TREAT THE PATIENT CORRESPONDINGLY IT IS ADVISED NOT TO REPLACE THE IMPLANT UNTIL THE INFLAMMATORY REACTION HAS PASSED COMPLETELY AND ITS CAUSE HAS BEEN ELIMINATED NECROSIS NECROSIS MAY INHIBIT WOUND HEALING AND REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION PERMANENT SCAR DEFORMITY MAY OCCUR AS A RESULT OF NECROSIS DO NOT USE MICROWAVE DIATHERMY IN PATIENTS WITH BEAST IMPLANTS MICROWAVE DIATHERMY HAS BEEN REPORTED TO CAUSE TISSUE NECROSIS SKIN EROSION AND IMPLANT EXTRUSION|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TRM240|12/10/2015|||DA|N|R||0HP|FTR|1.0|06/17/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2131883|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
4974939|6078051|D|1||HEALTH PROFESSIONAL REPORTS LEFT BREAST GROWTH HAD IMPLANT REMOVED BUT NOT CAPSULE FOUR YEARS LATER ALK NEGATIVE T-CELL LYMPHOMA DIAGNOSED IN REMOVED CAPSULE AND SEROMA NOT INVESTIGATED FOR MALIGN CELLS ALK NEGATIVE T-CELL LYMPHOMA IS CAPTURED AS LYMPHOMA AS ADDITIONAL PATHOLOGICAL MARKERS HAVE NOT BEEN PROVIDED HEALTH PROFESSIONAL ADDITIONALLY NOTED DAMAGE MUST BE TREATED WITH CHEMOTHERAPY AND RADIOTHERAPY|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|08/04/2015|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||LA AURORA DE HEREDIA|CS|ALLERGAN|||||||True
4665224|13168503|N|1||DEVICE LABELING ADDRESSES LYMPHOMA LYMPHOMAS INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - DOCUMENTATION MEDICAL SUGGESTS THAT THERE IS A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSALITY BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THIS DISEASE IS EXTREMELY RARE AND OCCURS IN WOMEN WITH OR WITHOUT BREAST IMPLANTS DEVICE LABELING ADDRESSES RUPTURE RUPTURE - PTS SHOULD BE INFORMED THAT THE FILLED BREAST IMPLANTS SILICONE GEL DOES NOT LAST A LIFETIME AND THAT IMPLANT RUPTURE IS A POSSIBILITY TO CONSIDER THE DECISION TO REMOVE A RUPTURED IMPLANT OR IS SUSPECTED TO BE TO BE TAKEN AFTER REVIEWING ALL CLINICAL DATA AVAILABLE AND AFTER CAREFUL THOUGHT ABOUT YOUR PT HOWEVER IF IMPLANT RUPTURE IS DIAGNOSED IT IS RECOMMENDED TO REMOVE THE IMPLANT DEVICE LABELING ADDRESSES LYMPHADENOPATHY ADDITIONAL COMPLICATIONS - AFTER A BREAST IMPLANT SURGERY THE FOLLOWING SITUATIONS MAY ARISE AND PERSIST AND TO VARY IN INTENSITY AND DURATION PAIN HEMATOMASEROMA CHANGES IN SENSATION IN NIPPLE AND BREAST EXTRUSION NECROSIS DELAYED WOUND HEALING TISSUE ATROPHY BREAST AND DEFORMITIES OF THE CHEST CALCIUM DEPOSITS FORM SOMETIMES IN THE CAPSULE TISSUE SURROUNDING THE IMPLANT WHICH IS MANIFESTED BY SYMPTOMS SUCH AS PAIN AND FIRMNESS LYMPHADENOPATHY HAS ALSO BEEN REPORTED IN SOME WOMEN WITH IMPLANTS|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|27-120341|04/06/2015||07/14/2014|DA|Y|Y||0HP|FTR|1.0|12/09/2010|NONE||1178535|||ARKLOW, COUNTY WICKLOW|EI|ALLERGAN|||||||True
4730396|17578076|D|1||JOURNAL ARTICLE ANAPLASTIC LARGE-CELL LYMPHOMA IN WOMEN WITH BREAST IMPLANTS DEJONG ET AL NOVEMBER 5 2008 JOURNAL AMERICAN MEDICAL ASSOCIATION REPORTS ANAPLASTIC LARGE T-CELL LYMPHOMA DIAGNOSED BILATERALLY STAGE II REPORT DEVICE WAS TEXTURED SILICONE MCGHAN|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|04/24/2015|||DA|N|R||0HP|FTR|1.0||nan||NI|LA AURORA DE HEREDIA|||CS|ALLERGAN|||||||True
6177062|62452555|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 B4 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL SEROMA BREAST LUMPS AND ERYTHEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION ERYTHEMA MAY ALSO OCCUR AS A NORMAL RESPONSE TO EXPANSION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6145451|61448260|N|1||IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP IS BEING PERFORMED FOR DEVICE RETURN IF DEVICE IS RETURNED ANALYSIS WILL BE PERFORMED AND RESULTS REPORTED IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE SEROMA AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE HISTORY RECORD DHR WAS PERFORMED AND DID NOT IDENTIFY ANY DEVIATIONS ERRORS OR OMISSIONS DURING MANUFACTURING PROCESS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM THIS WORK ORDER WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM120-280|12/05/2016||||N|R||0HP|FTR|1.0|06/13/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1287540|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6145512|63919660|N|1||B4 DEVICE WAS ANALYZED AT ALLERGAN B4 VISUAL ANALYSIS OF THE RETURNED DEVICE IDENTIFIED BROWN PARTICLES DELAMINATION OF THE PLUG STRAP LEAK TEST WAS PERFORMED AND NOT FOUND LEAKAGE A MICROSCOPIC ANALYSIS WAS PERFORMED WHICH IDENTIFY DELAMINATION OF THE PLUG STRAP DISK SHELL THE FILL TEST INSPECTION WAS PERFORMED THE RESULT IS NO BLOCKAGE BASED ON THE DEVICE ANALYSIS THE FINAL ASSESSMENT IS DELAMINATION OF THE PLUG STRAP DISK SHELL ASSESSED AS ADHESIVE FAILURE DEVICE HISTORY RECORD DHR DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM THIS WORK ORDER WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS THE EVENTS OF LYMPHOMA-ALCL CAPSULAR CONTRACTURE INFLAMMATION AND PAIN ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST FORMATION OF FIBROUS TISSUE AROUND AN IMPLANTED DEVICE IS A NORMAL PHYSIOLOGICAL RESPONSE FIBROUS CAPSULAR CONTRACTURE REMAINS A COMMON COMPLICATION FOLLOWING BREAST IMPLANT SURGERY AND IS ONE OF THE MOST COMMON REASONS FOR REOPERATION THE CAUSE OF CAPSULAR CONTRACTURE IS UNKNOWN HOWEVER IT IS MOST LIKELY MULTIFACTORIAL AND MAY BE MORE COMMON FOLLOWING INFECTION HAEMATOMA AND SEROMA CONTRACTURE DEVELOPS TO VARYING DEGREES UNILATERALLY OR BILATERALLY AND MAY OCCUR WITHIN WEEKS TO YEARS AFTER SURGERY CONTRACTURE OF THE FIBROUS CAPSULAR TISSUE SURROUNDING THE IMPLANT MAY CAUSE A RANGE OF SYMPTOMS INCLUDING FIRMNESS DISCOMFORT PAIN DISTORTION PALPABILITY ANDOR DISPLACEMENT SEVERE CASES ARE CONSIDERED THE MOST CLINICALLY SIGNIFICANT AND MAY REQUIRE SURGICAL INTERVENTION CAPSULAR CONTRACTURE MAY RECUR SUBSEQUENT TO CORRECTIVE SURGICAL PROCEDURES DO NOT TREAT CAPSULAR CONTRACTURE BY EXTERNAL COMPRESSION OR MASSAGE WHICH MAY RESULT IN IMPLANT DAMAGE DEFLATION FOLDS ANDOR HAEMATOMA Â¿AS EXPECTED FOLLOWING ANY INVASIVE SURGICAL PROCEDURE PAIN OF VARYING INTENSITY AND DURATION MAY OCCUR FOLLOWING IMPLANTATION IN ADDITION IMPROPER PLACEMENT SURGICAL TECHNIQUE OR CAPSULAR CONTRACTURE MAY RESULT IN PAIN ASSOCIATED WITH NERVE ENTRAPMENT OR INTERFERENCE WITH MUSCLE MOTION UNEXPLAINED PAIN MUST BE PROMPTLY INVESTIGATEDÂ¿|STYLE 168 SALINE FILLED BREAST IMPLANT|N-27-168211|12/05/2016||12/16/2016|DA|R|Y||0HP|FWM|1.0|09/03/2015|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||2013309|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6145512|61450145|N|1||THE DEVICE IS CURRENTLY BEING RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE SEROMA AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|STYLE 168 SALINE FILLED BREAST IMPLANT|N-27-168211|12/05/2016||12/16/2016|DA|R|Y||0HP|FWM|1.0|09/03/2015|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||2013309|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5644586|44853449|N|1||MEDWATCH SENT TO FDA ON 05102016 THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE OF THE EVENT DEVICE HAS NOT YET BEEN RECEIVED DEVICE HISTORY RECORD REVIEWED RESULTS STATE REVIEW OF DHR FOR B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM SAP WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS IN ADDITION DHR FOR SHELL RUN NUMBER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL Â¿ INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TSF365|05/10/2016||04/29/2016|DA|R|Y||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2740658|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6177002|62447626|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5896408|52758840|N|1||MEDWATCH SENT TO FDA ON 08232016 DEVICE HAS BEEN RETURNED DEVICE ANALYSIS IS NOT COMPLETE FINDINGS WILL BE SENT IN FOLLOW-UP REPORT THE EVENTS OF INFLAMMATION LYMPHOMA AND SWELLING ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING PRODUCT INFORMATION HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES THE REPORTED EVENTS AS FOLLOWS LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|27-110241|08/23/2016||08/23/2016|DA|R|Y||0HP|FTR|1.0|02/15/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||384466|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6106201|60020510|N|1||FOLLOW-UP IS BEING PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RECEIVED LAB ANALYSIS WILL BE PERFORMED AND THE RESULTS WILL BE REPORTED IN A SUPPLEMENTAL REPORT THE EVENTS OF SEROMA AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING ADDRESSES THE REPORTED EVENTS AS FOLLOWS LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION DEVICE HISTORY RECORD DHR REVIEW SUMMARY REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS IN ADDITION DHR FOR SHELL RUN NUMBER 8070302 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-MX120-325|11/16/2016||12/14/2016|DA|R|Y||0HP|FTR|1.0|07/15/2008|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||225212|KILBRIDE INDUSTRIAL ESTATE||ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
5670826|45647376|N|1||THE REPORTER OF THE EVENT WAS ASKED TO RETURN THE PRODUCT FOR ANALYSIS ALLERGAN HAS NOT RECEIVED THE PRODUCT AT THIS TIME THEREFORE NO ANALYSIS OR TESTING HAS BEEN DONE THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE HISTORY REVIEW REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS DHR FOR WORK ORDER B4 INDICATES THAT THERE WAS A REPROCESS ON THE PRIMARY PACKAGING OPERATION HOWEVER THIS WAS COMPLETED ON A DIFFERENT SERIAL NUMBER UNIT AND THIS HAS NO RELATION NEITHER CAN CAUSE THE REPORTED EVENT THE DHR ASSEMBLY REPORT WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE IN CONFORMANCE DURING MANUFACTURING PROCESS IN ADDITION DHR FOR SHELL RUNS NUMBER 10009114 AND 10009114 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURANCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MM125-320|05/20/2016|||DA|N|R||0HP|FTR|1.0|02/03/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2073435|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6176674|62457390|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL SEROMA AND MASS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6142978|61395222|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND DEATH ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/02/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6153182|61700300|N|1||B4 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHADENOPATHY AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/07/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5644581|44885546|N|1||THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE OF THE EVENT IT IS NOT KNOWN IF THE DEVICE WILL BE RETURNED MISSING INFORMATION INCLUDES DEVICE SERIAL NUMBER IMPLANT DATE DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL  INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|05/10/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||nan|||||||True
6199283|63133499|N|1||IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP IS BEING PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM130-360|12/22/2016|||DA|N|R||0HP|FTR|1.0|11/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||352966|KILBRIDE INDUSTRIAL ESTATE||ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
6023404|57191542|N|1||FOLLOW-UP IS BEING PERFORMED FOR DEVICE RETURN THE EVENTS OF LYMPHOMA AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT AND PRODUCT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES THE REPORTED EVENTS AS FOLLOWS LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-FX155-775|10/12/2016||03/02/2017|DA|R|Y||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2379964|900 PARKWAY GLOBAL PARK|ZONA FRANCA|ARKLOW, COUNTY WICKLOW|CS|ALLERGAN (COSTA RICA)|||||||True
5904549|53036936|N|1||MEDWATCH SENT TO FDA ON 08252016 IN RESPONSE TO FDA REPORT NUMBER MW5063635 B4 DEVICE HAS BEEN CONFIRMED AS AVAILABLE FOR RETURN BUT HAS NOT YET BEEN RECEIVED THE EVENTS OF LYMPHOMA EDEMA VISIBILITYPALPABILITY SENSATION INCREASE AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES THE REPORTED EVENTS AS FOLLOWS LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION SENSATION IN THE NIPPLE AND BREAST CAN INCREASE OR DECREASE AFTER IMPLANT SURGERY IS TYPICALLY LOST AFTER COMPLETE MASTECTOMY WHERE THE NIPPLE ITSELF IS REMOVED AND CAN BE SEVERELY LESSENED BY PARTIAL MASTECTOMY|CUI TEXTURED SILICONE GEL FILLED BREAST IMPLANT|MHP-460|08/25/2016||09/29/2016|DA|R|Y||0HP|FTR|1.0|05/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||303203|KILBRIDE INDUSTRIAL ESTATE|ZONA FRANCA|ARKLOW, COUNTY WICKLOW||ALLERGAN (ARKLOW)|||||||True
5884313|52381106|N|1||FOLLOW-UP IS NOT POSSIBLE IN THIS CASE NO DEVICE HISTORY RECORD WAS REQUESTED AS DEVICE INFORMATION IS UNKNOWN DEVICE LABELING ADDRESSES THE REPORTED EVENTS AS FOLLOWS LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST ERYTHEMA MAY ALSO OCCUR AS A NORMAL RESPONSE TO EXPANSION THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|08/17/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5595588|43273124|N|1||THE EVENTS OF SEROMA-LATE AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLY CAUSE FOR THIS EVENT THE DEVICE WILL NOT BE RETURNED DEVICE LABELING ADDRESSES LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH HEMATO-ONCOLOGIST|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|27-FF140-535|04/21/2016||||N|R||0HP|FTR|1.0|09/15/2007|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||165721|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5896385|52760206|N|1||MEDWATCH SENT TO FDA ON 08232016 DEVICE HAS BEEN RETURNED DEVICE ANALYSIS IS NOT COMPLETE FINDINGS WILL BE SENT IN FOLLOW-UP REPORT THE EVENTS OF INFLAMMATION LYMPHOMA AND SWELLING ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING PRODUCT INFORMATION HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING ADDRESSES THE REPORTED EVENTS AS FOLLOWS LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|27-110241|08/23/2016||08/23/2016|DA|R|Y||0HP|FTR|1.0|02/15/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||384466|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6145514|64146442|N|1||B4 DEVICE WAS ANALYZED AT ALLERGAN B4 VISUAL ANALYSIS OF THE RETURNED DEVICE IDENTIFIED FLAT CREASES WHITE PARTICLES IN DEVICE OUTER SURFACE AND ONE CURVED OPENING IN THE POSTERIOR A LEAK TEST WAS PERFORMED WHICH IDENTIFIED OPENING A MICROSCOPIC ANALYSIS WAS PERFORMED WHICH IDENTIFY ONE OPENING STRIATED CURVED ASSESSED AS SURGICAL DAMAGE AND PARTIAL DELAMINATION OF PLUG STRAP DISK SHELL DUE TO ADHESIVE FAILURE FILL INSPECTION WAS PERFORMED AND IDENTIFIED NO BLOCKAGE IN THE VALVE BASED ON THE DEVICE ANALYSIS THE FINAL ASSESSMENT IS ONE OPENING STRIATED CURVED ASSESSED AS SURGICAL DAMAGE PARTIAL DELAMINATION OF PLUG STRAP DISK SHELL DUE TO ADHESIVE FAILURE DEVICE HISTORY RECORD DHR DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM THIS WORK ORDER WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS THE EVENTS OF LYMPHOMA-ALCL CAPSULAR CONTRACTURE INFLAMMATION AND PAIN ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST FORMATION OF FIBROUS TISSUE AROUND AN IMPLANTED DEVICE IS A NORMAL PHYSIOLOGICAL RESPONSE FIBROUS CAPSULAR CONTRACTURE REMAINS A COMMON COMPLICATION FOLLOWING BREAST IMPLANT SURGERY AND IS ONE OF THE MOST COMMON REASONS FOR REOPERATION THE CAUSE OF CAPSULAR CONTRACTURE IS UNKNOWN HOWEVER IT IS MOST LIKELY MULTIFACTORIAL AND MAY BE MORE COMMON FOLLOWING INFECTION HAEMATOMA AND SEROMA CONTRACTURE DEVELOPS TO VARYING DEGREES UNILATERALLY OR BILATERALLY AND MAY OCCUR WITHIN WEEKS TO YEARS AFTER SURGERY CONTRACTURE OF THE FIBROUS CAPSULAR TISSUE SURROUNDING THE IMPLANT MAY CAUSE A RANGE OF SYMPTOMS INCLUDING FIRMNESS DISCOMFORT PAIN DISTORTION PALPABILITY ANDOR DISPLACEMENT SEVERE CASES ARE CONSIDERED THE MOST CLINICALLY SIGNIFICANT AND MAY REQUIRE SURGICAL INTERVENTION CAPSULAR CONTRACTURE MAY RECUR SUBSEQUENT TO CORRECTIVE SURGICAL PROCEDURES DO NOT TREAT CAPSULAR CONTRACTURE BY EXTERNAL COMPRESSION OR MASSAGE WHICH MAY RESULT IN IMPLANT DAMAGE DEFLATION FOLDS ANDOR HAEMATOMA Â¿AS EXPECTED FOLLOWING ANY INVASIVE SURGICAL PROCEDURE PAIN OF VARYING INTENSITY AND DURATION MAY OCCUR FOLLOWING IMPLANTATION IN ADDITION IMPROPER PLACEMENT SURGICAL TECHNIQUE OR CAPSULAR CONTRACTURE MAY RESULT IN PAIN ASSOCIATED WITH NERVE ENTRAPMENT OR INTERFERENCE WITH MUSCLE MOTION UNEXPLAINED PAIN MUST BE PROMPTLY INVESTIGATEDÂ¿|STYLE 168 SALINE FILLED BREAST IMPLANT|N-27-168211|12/05/2016||12/16/2016|DA|R|Y||0HP|FWM|1.0|09/09/2015|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||2013310|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6145514|61451047|N|1||THE DEVICE IS CURRENTLY BEING RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE SEROMA AND LYMPHOMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|STYLE 168 SALINE FILLED BREAST IMPLANT|N-27-168211|12/05/2016||12/16/2016|DA|R|Y||0HP|FWM|1.0|09/09/2015|PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||2013310|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5690994|46271112|N|1||MEDWATCH SENT TO FDA ON 06012016 THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE OF THIS EVENT IT IS NOT KNOWN IF THE DEVICE WILL BE RETURNED PATIENT INFORMATION WAS NOT PROVIDED DEVICE LABELING ADDRESSES LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|STYLE 110 SILICONE GEL FILLED BREAST IMPLANT|27-110391|06/01/2016|||DA|N|R||0HP|FTR|1.0|03/15/2008|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||201218|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5956972|54992702|N|1||THE EVENTS OF LYMPHOMA AND SEROMA-LATE ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE OF THE EVENTS THE DEVICE WILL NOT BE RETURNED AS IT WAS DISCARDED DEVICE LABELING ADDRESSES LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST DEVICE HISTORY RECORD STATES REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS  ALL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT FROM ORACLE WAS VERIFIED AND THERE WAS NO SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS IN ADDITION DHR FOR SHELL RUNS NUMBER B4 DID NOT IDENTIFY ANY ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ERIR NUMBER B4 WAS REFERENCED IN DHR RECORD FOR SHELL RUN NUMBER B4 THIS ER IS RELATED TO TAPERING PROCESS HOWEVER THERE IS NO IMPACT TO THE DEVICES BASED ON THE REGULATORY REQUIREMENTS ERIR NUMBER B4 WAS REFERENCED IN DHR RECORD FOR SHELL RUN NUMBER B4 THIS ER IS RELATED TO TAPERING PROCESS HOWEVER THERE IS NO IMPACT TO THE DEVICES BASED ON THE REGULATORY REQUIREMENTS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS|STYLE 150 EXPANDABLE BREAST IMPLANT|27-150496|09/16/2016|||DA|N|R||0HP|FTR|1.0|02/14/2011|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1205583|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6180550|62543961|N|1||IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP IS BEING PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENT OF LYMPHOMA IS PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/16/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6177211|62456167|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 B4 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL SEROMA LUMP AND ERYTHEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION ERYTHEMA MAY ALSO OCCUR AS A NORMAL RESPONSE TO EXPANSION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176804|62446182|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6148888|61547075|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA IN A PATIENT WITH LI-FRAUMENI SYNDROMEÂ¿ BY YI-SHAN LEE ARMANDO FILIE DIANE ARTHUR ANTONIO T FOJO AND ELAINE S JAFFE PUBLISHED IN HISTOPATHOLOGY 67 923Â¿935 IN 2015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE SEROMA CANCER AND LYMPHOMA-ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/06/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6176705|62451142|N|1||B4 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176730|62445769|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176886|62453116|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA SEROMA AND MASS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176855|62446706|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/15/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6176798|62453768|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6153200|61697779|D|1||LITERATURE ARTICLE Â¿COMPLETE SURGICAL EXCISION IS ESSENTIAL FOR THE MANAGEMENT OF PATIENTS WITH BREAST IMPLANTÂ¿ASSOCIATED ANAPLASTIC LARGE-CELL LYMPHOMAÂ¿ REPORTS Â¿87 PATIENTS WITH BI-ALCL INCLUDING 50 PREVIOUSLY REPORTED IN THE LITERATURE AND 37 UNREPORTEDÂ¿ ARTICLE CONTINUES TO STATE Â¿BREAST IMPLANTÂ¿ASSOCIATED ANAPLASTIC LARGE-CELL LYMPHOMA BI-ALCL IS A RARE TYPE OF T-CELL LYMPHOMA THAT ARISES AROUND BREAST IMPLANTS THE OPTIMAL MANAGEMENT OF THIS DISEASE HAS NOT BEEN ESTABLISHED THE GOAL OF THIS STUDY IS TO EVALUATE THE EFFICACY OF DIFFERENT THERAPIES USED IN PATIENTS WITH BI-ALCL TO DETERMINE AN OPTIMAL TREATMENT APPROACHÂ¿ Â¿THE MEDIAN AND MEAN FOLLOW-UP TIMESWERE 45 AND 30 MONTHS RESPECTIVELY RANGE 3 TO 217 MONTHS THE MEDIAN OVERALL SURVIVAL OS TIME AFTER DIAGNOSIS OF BI-ALCL WAS 13 YEARS AND THE OS RATE WAS 93AND 89AT 3 AND 5 YEARS RESPECTIVELY PATIENTS WITH LYMPHOMA CONFINED BY THE FIBROUS CAPSULE SURROUNDING THE IMPLANT HAD BETTER EVENT-FREE SURVIVAL EFS AND OS THAN DID PATIENTS WITH LYMPHOMA THAT HAD SPREAD BEYOND THE CAPSULE P = 03 PATIENTS WHO UNDERWENT A COMPLETE SURGICAL EXCISION THAT CONSISTED OF TOTAL CAPSULECTOMY WITH BREAST IMPLANT REMOVAL HAD BETTER OSP = 022 AND EFSP = 014 THAN DID PATIENTS WHO RECEIVED PARTIAL CAPSULECTOMY SYSTEMIC CHEMOTHERAPY OR RADIATION THERAPYÂ¿ CYTOLOGICAL MARKERS ALK- AND CD30+ HAVE BEEN REPORTED THERE IS CURRENTLY NO WAY TO DETERMINE WHICH CASES HAD WHICH THERAPIES OR DEVICE TYPE THIS REPORT WILL CAPTURE 37 UNREPORTED CASES OF ALCL  LYMPHOMA|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/07/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
5488680|39947737|N|1||DEVICE LABELING ADDRESSES LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST STUDIES EVALUATING THE CAPSULES AROUND TEXTURED EXPANDERS HAVE REPORTED POSSIBLE SILICONE PARTICLES WITH GIANT CELLS INDICATIVE OF LOCAL AND NON SPECIFIC FOREIGN BODY REACTION AND SILICONE GRANULOMA FORMATION|STYLE 120 SILICONE GEL FILLED BREAST IMPLANT|27-120301|03/09/2016|||DA|N|R||0HP|FTR|1.0|02/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||276452|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5607727|43625363|N|1||MEDWATCH SENT TO FDA ON 04262016 THE REPORTER OF THE EVENT WAS ASKED TO RETURN THE PRODUCT FOR ANALYSIS ALLERGAN HAS NOT RECEIVED THE PRODUCT AT THIS TIME THEREFORE NO ANALYSIS OR TESTING HAS BEEN DONE THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT AND PATIENT DETAILS HAS BEEN REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|MF-410420|04/26/2016||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5672723|45694207|N|1||MEDWATCH SENT TO THE FDA ON 05232016 THE REPORTER OF THIS EVENT WAS NOT IDENTIFIED BY THE REGULATORY AGENCY ALLERGAN HAS NOT RECEIVED THE PRODUCT AT THIS TIME THEREFORE NO ANALYSIS OR TESTING HAS BEEN DONE THE EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT THE REPORTER OF THIS EVENT WAS NOT IDENTIFIED BY THE REGULATORY AGENCY THEREFORE NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE HISTORY REVIEW REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ALL DEVICES WERE CONFORMANCE DURING MANUFACTURING PROCESS IN ADDITION DHR FOR SHELL RUN NUMBER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM125-320|05/23/2016||||N|R||0HP|FTR|1.0|09/19/2010|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||1139476|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6143087|61396766|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND LUMPNODULE ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/02/2016|||DA|N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6177272|62460334|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK SALINE IMPLANT|UNK SALINE IMPLANT|12/15/2016||||*|*||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|||||UNKNOWN MANUFACTURER|||||||True
6139636|61290117|N|1||IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP HAS BEEN PERFORMED AND DEVICE WILL NOT BE RETURNED IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT IN A SUPPLEMENTAL REPORT EVENT OF HEMATOMA WAS PREVIOUSLY REPORTED VIA RESPONSIVE PSR ON B6 2016 THE EVENTS OF LATE SEROMA AND LYMPHOMA-ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|INSPIRA TEXTURED SILICONE GEL FILLED BREAST IMPLANT|N-TRLP250|12/01/2016||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2429970|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6176870|62452743|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6139164|61260978|N|1||ARTICLE CITATION Â¿MARKED EOSINOPHILIA AS INITIAL PRESENTATION OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMAÂ¿ BY NICOLA OROFINO FRANCESCA GUIDOTTI DANIELE CATTANEO MARIARITA SCIUMÃ UMBERTO GIANELLI AGOSTINO CORTELEZZI  ALESSANDRA LURLO PUBLISHED IN LEUKEMIA  LYMPHOMA PUBLISHED ELECTRONICALLY ON 17MAR2016 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE SEROMA LYMPHOMA-ALCL PRURITUS AND EOSINOPHILIA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK MAMMARY IMPLANT|UNK MAMMARY IMPLANT|12/01/2016||||N|R||0HP|FWM|1.0||PROSTHESIS, BREAST, INFLATABLE, INTERNAL, SALINE||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6144474|61423058|N|1||ARTICLE CITATION Â¿WHOLE EXOME SEQUENCING REVEALS ACTIVATING JAK1 AND STAT3 MUTATIONS IN BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA ANAPLASTIC LARGE CELL LYMPHOMA BY PIERS BLOMBERY ELLA R THOMPSON KATE JONES GISELA MIR ARNAU STEPHEN LADE JOHN F MARKHAM JASON LI ANAND DEVA RICKY W JOHNSTONE AMIT KHOT H MILES PRINCE AND DAVID WESTERMAN PUBLISHED IN HAEMATOLOGICA ELECTRONICALLY PUBLISHED SEPTEMBER 2016 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LATE SEROMA AND LYMPHOMA-ALCL ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/05/2016||||N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5620587|44062744|D|1||EXPLANTING PHYSICIAN REPORTED LEFT SIDE ONSET OF RECURRENT SEROMAS APPROXIMATELY 10 YEARS AFTER IMPLANTATION THE SEROMAS WERE DRAINED ON THREE OCCASIONS APPROXIMATELY FOUR MONTHS AFTER THE ONSET OF THE SEROMAS AN AXILLARY MASS APPEARED WHICH WAS BIOPSIED AND A DIAGNOSIS OF ANAPLASTIC T-CELL LYMPHOMA WAS ESTABLISHED MULTIPLE ANAPLASTIC CELLS WERE IDENTIFIED WHICH SHOWED WEAK CD2 CD3 AND CD4 EXPRESSION AND STRONG CD30 TIA-1 AND PERFORIN EXPRESSION ALK WAS NEGATIVE FINE NEEDLE ASPIRATION BIOPSY REVEALED THE FOLLOWING ADDITIONAL DIAGNOSIS CYTOLOGIC FINDINGS COMPATIBLE WITH LYMPH NODE INVOLVEMENT BY LYMPHOPROLIFERATIVE PROCESS CD30-POSITIVE PROBABLY HODGKINS LYMPHOMA DIAGNOSTIC TESTING ADDITIONALLY REVEALED LEFT SIDE LYMPHANGITIS GLOBULAR ADENOPATHIES CAPSULITIS HISTIOCYTES OF EPITHELIOID ASPECT AS PART OF GRANULOMAS AND PRESENCE OF LARGE CELLS LARGE AREAS OF NECROSIS AND A Â¿PERIPROSTHETIC COLLECTIONÂ¿ DIAGNOSTIC TESTING ALSO REVEALED NON SIDE-SPECIFIC EVENTS OF GOITER AND Â¿LUNG PARENCHYMA WITH MODERATE PARASEPTAL AND CENTRILOLOBULAR EMPHYSEMA IN THE MIDDLE AND UPPER FIELDSÂ¿ AND Â¿LAMINAR ATELECTASISÂ¿ APPROXIMATELY ONE MONTH AFTER THE DIAGNOSIS THE PATIENT UNDERWENT LEFT SIDE IMPLANT REMOVAL WITH CAPSULECTOMY AND A TOTAL MASTECTOMY OF THE LEFT BREAST IN LIGHT OF THE PRESENCE OF AN INDURATED BREAST MASS EXTENDING TO THE AXILLA PHYSICIAN NOTED THAT BOTH IMPLANTS WERE INTACT AND THAT Â¿THE CAPSULE WAS INTEGRATED INTO THE TUMOURÂ¿ THE HISTOLOGIC DIAGNOSIS OF ANAPLASTIC T-CELL LYMPHOMA WAS RETAINED PHYSICIAN NOTED AFTER SURGERY IS OBSERVED CLINICAL WORSENING OF THE PATIENT RESPIRATORY FAILURE SECONDARY TO LEFT PLEURAL EFFUSION RESULTING IN ADMISSION IN THE ICU AND THORACIC DRAINAGE THROUGH RECURRENT CHEST TUBE DRAINAGE WAS REQUIRED ON 3 OCCASIONS AFTER THE PATIENTS FIRST STAY IN THE ICU THE PATIENT GOES TO THE FIRST FLOOR AND RECEIVES THE FIRST CYCLE OF CHEMOTHERAPY SHOWING GRADE IV NEUTROPENIA AND DIARRHOEA AFTER THE SECOND CHEMOTHERAPY THE PATIENT SHOWS MARKED CLINICAL DETERIORATION WITH SUSPICIOUS OF TUMOUR LYSIS SYNDROME METABOLIC ACIDOSIS AND RENAL FAILURE THIS RESULTS IN A SECOND ADMISSION IN THE ICU THE PATIENT DIED APPROXIMATELY FIVE WEEKS AFTER IMPLANT REMOVAL THIS MEDWATCH REPRESENTS THE LEFT SIDE SEE MFR  9617229-2016-00036 FOR THE RIGHT SIDE|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM125-320|04/29/2016|||DA|N|R||0HP|FTR|1.0|06/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||306845|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5620587|44062743|N|1||B4 THE PHYSICIAN NOTED THE DEVICE IS NO LONGER AVAILABLE FOR RETURN THEREFORE ALLERGAN WILL NOT RECEIVE IT AND NO ANALYSIS OR TESTING WILL BE DONE THE REPORTED EVENTS ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL Â¿ INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION NECROSIS NECROSIS MAY INHIBIT WOUND HEALING AND REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION PERMANENT SCAR DEFORMITY MAY OCCUR AS A RESULT OF NECROSIS DO NOT USE MICROWAVE DIATHERMY IN PATIENTS WITH BREAST IMPLANTS MICROWAVE DIATHERMY HAS BEEN REPORTED TO CAUSE TISSUE NECROSIS SKIN EROSION AND IMPLANT EXTRUSION|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM125-320|04/29/2016|||DA|N|R||0HP|FTR|1.0|06/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||306845|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
5620587|49100603|D|1||EXPLANTING PHYSICIAN REPORTED LEFT SIDE ONSET OF RECURRENT SEROMAS APPROXIMATELY 10 YEARS AFTER IMPLANTATION THE SEROMAS WERE DRAINED ON THREE OCCASIONS APPROXIMATELY FOUR MONTHS AFTER THE ONSET OF THE SEROMAS AN AXILLARY MASS APPEARED WHICH WAS BIOPSIED AND A DIAGNOSIS OF ANAPLASTIC T-CELL LYMPHOMA WAS ESTABLISHED MULTIPLE ANAPLASTIC CELLS WERE IDENTIFIED WHICH SHOWED WEAK CD2 CD3 AND CD4 EXPRESSION AND STRONG CD30 TIA-1 AND PERFORIN EXPRESSION ALK WAS NEGATIVE FINE NEEDLE ASPIRATION BIOPSY REVEALED THE FOLLOWING ADDITIONAL DIAGNOSIS CYTOLOGIC FINDINGS COMPATIBLE WITH LYMPH NODE INVOLVEMENT BY LYMPHOPROLIFERATIVE PROCESS CD30-POSITIVE PROBABLY HODGKINS LYMPHOMA DIAGNOSTIC TESTING ADDITIONALLY REVEALED LEFT SIDE LYMPHANGITIS GLOBULAR ADENOPATHIES CAPSULITIS HISTIOCYTES OF EPITHELIOID ASPECT AS PART OF GRANULOMAS AND PRESENCE OF LARGE CELLS LARGE AREAS OF NECROSIS AND A Â¿PERIPOSTHETIC COLLECTIONÂ¿ DIAGNOSTIC TESTING ALSO REVEALED NON SIDE-SPECIFIC EVENTS OF GOITER AND Â¿LUNG PARENCHYMA WITH MODERATE PARASEPTAL AND CENTRILOLOBULAR EMPHYSEMA IN THE MIDDLE AND UPPER FIELDSÂ¿ AND Â¿LAMINAR ATELECTASISÂ¿ APPROXIMATELY ONE MONTH AFTER THE DIAGNOSIS THE PATIENT UNDERWENT LEFT SIDE IMPLANT REMOVAL WITH CAPSULECTOMY AND A TOTAL MASTECTOMY OF THE LEFT BREAST IN LIGHT OF THE PRESENCE OF AN INDURATED BREAST MASS EXTENDING TO THE AXILLA PHYSICIAN NOTED THAT BOTH IMPLANTS WERE INTACT AND THAT Â¿THE CAPSULE WAS INTEGRATED INTO THE TUMOURÂ¿ THE HISTOLOGIC DIAGNOSIS OF ANAPLASTIC T-CELL LYMPHOMA WAS RETAINED PHYSICIAN NOTED AFTER SURGERY IS OBSERVED CLINICAL WORSENING OF THE PATIENT RESPIRATORY FAILURE SECONDARY TO LEFT PLEURAL EFFUSION RESULTING IN ADMISSION IN THE ICU AND THORACIC DRAINAGE THROUGH RECURRENT CHEST TUBE DRAINAGE WAS REQUIRED ON 3 OCCASIONS AFTER THE PATIENTS FIRST STAY IN THE ICU THE PATIENT GOES TO THE FIRST FLOOR AND RECEIVES THE FIRST CYCLE OF CHEMOTHERAPY SHOWING GRADE IV NEUTROPENIA AND DIARRHOEA AFTER THE SECOND CHEMOTHERAPY THE PATIENT SHOWS MARKED CLINICAL DETERIORATION WITH SUSPICIOUS OF TUMOUR LYSIS SYNDROME METABOLIC ACIDOSIS AND RENAL FAILURE THIS RESULTS IN A SECOND ADMISSION IN THE ICU THE PATIENT DIED APPROXIMATELY FIVE WEEKS AFTER IMPLANT REMOVAL THIS MEDWATCH REPRESENTS THE LEFT SIDE SEE MFR  9617229-2016-00036 FOR THE RIGHT SIDE|STYLE 410 SILICONE GEL FILLED BREAST IMPLANT|ST-MM125-320|04/29/2016|||DA|N|R||0HP|FTR|1.0|06/15/2009|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||306845|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6176830|62457610|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6167285|62187249|N|1||Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND ERYTHEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST ERYTHEMA MAY ALSO OCCUR AS A NORMAL RESPONSE TO EXPANSION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/12/2016|||DA|*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6143032|61396906|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL AND LATE SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/02/2016|||DA|N|R||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6167248|62147366|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA ALCL LATE SEROMA AND LUMPNODULE ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANATION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/12/2016|||DA|*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
5695364|46431598|N|1||MEDWATCH SENT TO THE FDA ON 06022016 SEROMA AND RUPTURE WERE INITIALLY SUBMITTED TO THE FDA VIA 410 PSR ON 01212016 DEVICE WAS FOUND TO BE INTACT RUPTURE DID NOT OCCUR THE EVENT OF LYMPHOMA IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT PHYSICIAN HAS CONFIRMED THE DEVICE WILL NOT BE RETURNED PHYSICIAN HAS NOT RESPONDED TO FOLLOW-UP ATTEMPTS FOR COMPLETION OF ALCL QUESTIONNAIRE AND PATHOLOGY REPORTS DEVICE HISTORY REVIEW REVIEW OF DHR FOR WORK ORDER B4 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING MANUFACTURING PROCESS ALL GEL BREAST IMPLANTS WERE REVIEWED AS PART OF THE ASSEMBLY OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT ASSEMBLY MET THE REQUIRED SPECIFICATIONS THE DHR ASSEMBLY REPORT WAS VERIFIED AND THERE WAS NOT ANY SCRAP RELATED WITH REPORTED EVENT ONLY ONE DEVICE WAS SCRAPPED IN ADDITION DHR FOR SHELL RUNS NUMBER 10008414 AND 10008555 DID NOT IDENTIFY ANY DEVIATIONS ERRORS OMISSIONS OR NON-CONFORMANCES DURING SHELL FABRICATION PROCESS ALL SHELLS WERE REVIEWED AS PART OF THE SHELL FABRICATION OPERATIONS AND THESE TASKS WERE PERFORMED ACCORDING TO APPLICABLE CURRENT PROCEDURES TO ENSURE THAT FABRICATION MET THE REQUIRED SPECIFICATIONS ACCORDING TO THE INFORMATION GATHERED DURING THE DHR REVIEW THERE IS ENOUGH EVIDENCE TO SUPPORT THAT DEVICES FROM WORK ORDER B4 WERE ASSEMBLED IN ACCORDANCE WITH ALLERGAN MEDICAL PROCEDURES AND SPECIFICATIONS THE REPORTED DEVICE WAS INTACT AT THE TIME OF PRODUCTION AND MET THE REQUIRED SPECIFICATIONS DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMA ALCL Â¿ INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF THE REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST|STYLE 410 COHESIVE SILICONE GEL FILLED BREAST IMPLANT|N-27-MX135-445|06/02/2016||||N|R||0HP|FTR|1.0|01/24/2016|PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||2070807|900 PARKWAY GLOBAL PARK|ZONA FRANCA||CS|ALLERGAN (COSTA RICA)|||||||True
6176648|62440609|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 B4 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF DEATH LYMPHOMA ALCL SEROMA LUMP AND ERYTHEMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION ERYTHEMA MAY ALSO OCCUR AS A NORMAL RESPONSE TO EXPANSION|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
6176965|62446267|N|1||ARTICLE CITATION Â¿BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA TWO DISTINCT CLINICOPATHOLOGICAL VARIANTS WITH DIFFERENT OUTCOMESÂ¿ BY C LAURENT A DELAS P GAULARD C HAIOUN A MOREAU L XERRI A TRAVERSE-GLEHEN T ROUSSET I QUINTIN-ROUE T PETRELLA J F EMILE N AMARA P ROCHAIX M P CHENARD-NEU A M TASEI E MENET H CHOMARAT V COSTES L ANDRAC-MEYER J F MICHIELS C CHASSAGNE-CLEMENT L DE LEVAL P BROUSSET G DELSOL  L LAMANT PUBLISHED IN ANNALS OF ONCOLOGY ELECTRONICALLY PUBLISHED 11232015 IT WAS NOT POSSIBLE TO FULLY INVESTIGATE OR CONFIRM THE ALLEGED EVENT AS THE PRODUCT WAS NOT RETURNED TO ALLERGAN FOR ANALYSIS FOLLOW-UP WILL BE PERFORMED TO REQUEST DEVICE RETURN IF DEVICE IS RETURNED IT WILL BE ANALYZED AND RESULTS SENT TO THE FDA IN A SUPPLEMENTAL REPORT THE EVENTS OF LYMPHOMA-ALCL AND SEROMA ARE PHYSIOLOGICAL COMPLICATIONS AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THESE EVENTS FURTHER INFORMATION FROM THE REPORTER REGARDING EVENT PRODUCT OR PATIENT DETAILS WILL BE REQUESTED NO ADDITIONAL INFORMATION IS AVAILABLE AT THIS TIME REPORTED EVENTS ARE ADDRESSED IN DEVICE LABELING LYMPHOMA INCLUDING ANAPLASTIC LARGE T-CELL LYMPHOMAALCL - INFORMATION FROM MEDICAL LITERATURE HAS SUGGESTED A POSSIBLE ASSOCIATION WITHOUT EVIDENCE OF CAUSATION BETWEEN BREAST IMPLANTS AND THE VERY RARE OCCURRENCE OF ALCL IN THE BREAST THE DISEASE IS EXCEPTIONALLY RARE MAY PRESENT AS A LATE OCCURRING PERI-PROSTHETIC SEROMA AND OCCURS IN WOMEN WITH AND WITHOUT BREAST IMPLANTS SPECIFIC TESTING IS NEEDED TO DISTINGUISH ALCL FROM BREAST CANCER THE MAJORITY OF REPORTED CASES HAD AN INDOLENT CLINICAL COURSE FOLLOWING CAPSULECTOMY WITH OR WITHOUT ADJUVANT THERAPY WHICH IS GENERALLY UNCHARACTERISTIC OF SYSTEMIC ALCL TREATMENT SHOULD BE DETERMINED IN CONSULTATION WITH A HEMATO-ONCOLOGIST HAEMATOMASEROMA MAY OCCUR IN THE POSTOPERATIVE PERIOD INHIBITING WOUND HEALING OR HAVE DELAYED ONSET EITHER OF WHICH MAY REQUIRE SURGICAL CORRECTION ANDOR EXPLANTATION GEL IMPLANTS MAY RUPTURE AND SALINE OR GELSALINE IMPLANTS MAY DEFLATE AT ANY TIME AND REQUIRE REPLACEMENT OR REVISION SURGERY AS RUPTURES ARE MOST OFTEN CLINICALLY SILENT A RADIOLOGICAL ASSESSMENT MAY BE REQUIRED TO AID DIAGNOSIS|UNK GEL BREAST IMPLANT|UNK GEL BREAST IMPLANT|12/15/2016||||*|*||0HP|FTR|1.0||PROSTHESIS, BREAST, NONINFLATABLE, INTERNAL, SILICONE GEL-FILLED||NI|||||UNKNOWN MANUFACTURER|||||||True
